Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, February 16 2021 - 09:00
Menarini Silicon Biosystems announces launch of CellMag(TM) product line offering affordable Gold Standard Circulating Tumor Cells capture
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Feb. 16, 2021 /PRNewswire-AsiaNet/ --

CELLMAG – a cost effective, manual and simple approach for the enrichment and 
staining of extremely rare cells from blood 

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell 
technologies, announced today the launch of its innovative CellMag product line 
for the manual enrichment and staining of rare circulating tumor cells (CTCs). 
This new product line, composed of the CellMag CTC Epithelial Cell kit, a 
magnetic tool and consumables, will allow all liquid biopsy and CTCs 
Laboratories to have access to a manual system using the same ferrofluid 
technology offered by the Gold Standard CELLSEARCH system.

This easy to use technology offers researchers who work on translational 
projects a reliable tool to study the heterogeneous biology of CTCs, whose 
presence in blood has been associated with poor prognosis in metastatic 

Despite different available methods to capture CTCs, only the information 
obtained from CTCs that have been captured by the CELLSEARCH ferrofluid 
technology have shown a robust clinical value in different settings1. Research 
laboratories will appreciate the convenience, simplicity and affordability of 
CellMag. Researchers can analyze and characterize enriched CTCs from a 
molecular perspective with a high level of specificity, gaining valuable 
insights into how certain tumors progress and disseminate throughout the body. 
“CellMag is a manual system for the capture and enhancement of CTCs using the 
established ferrofluid technology. Perfectly tailored to our research needs, it 
offers a manual version of the reference CELLSEARCH platform” said Dr. 
Catherine Alix-Panabières, Associate Professor and Director of the Laboratory 
of Rare Human Circulating Cells (LCCRH) at the University Medical Center of 
Montpellier, France. 

The CellMag CTC Ephitelial Cell kit allows research centers, focusing on liquid 
biopsies, to conduct highly specific, established and standardized 
immunomagnetic enrichment and staining of CTCs in peripheral blood. Following 
the positive selection of enriched cells, performed by capturing cells through 
ferrofluids labeled with antibodies that target the (EpCAM) antigen, the 
staining procedure delivers cells that are ready for enumeration, isolation and 
downstream analysis. The final step of cell sorting can be performed by the 
DEPArray system or other downstream applications including flow cytometry, 
fluorescent microscopy or molecular and phenotype analyses.

For Fabio Piazzalunga, President and CEO of Menarini Silicon Biosystems: “Our 
manual CellMag product line allows all liquid biopsy and CTCs Laboratories to 
reach high specificity in cell enrichment and staining, leveraging the 
established CELLSEARCH ferrofluid technology. With this simple and standardized 
solution we are committed to helping all researchers develop scientific 
understanding and improve medical knowledge related to human diseases.” 

The CellMag product line family will be expanded in the coming months to offer 
a series of additional kits for the enrichment of other rare cell types.

CELLMAG is intended for Research Use Only (RUO) – not for use in diagnostic 
procedures. This product line allows for highly specific and standardized cell 
enrichment and staining. Cells captured with the CellMag technology are 
comparable to those captured with the CELLTRACKS(R) AUTOPREP(R) System. The 
product line is composed of an epithelial CTC kit, for ferrofluid-based EpCAM 
positive CTC enrichment, a magnetic tool and consumables. The process involves 
a sample preparation phase, followed by the magnetic separation of CTCs, sample 
washing, permeabilization and staining.

For more information on the CELLMAG product line, please refer to

About Menarini Silicon Biosystems
Menarini Silicon Biosystems offers unique rare cell technologies and solutions 
that provide clinical researchers with access to unparalleled resolution in the 
study of cells and their molecular characterization.
Menarini Silicon Biosystems [], based in 
Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary 
of the Menarini Group, a multinational pharmaceutical, biotechnology and 
diagnostics company headquartered in Florence, Italy, with more than 17,000 
employees in 140 countries.

  Riethdorf S, O'Flaherty L, Hille C, Pantel K. Clinical applications of the 
CellSearch platform in cancer patients. Adv Drug Deliv Rev. 2018 Feb 
1;125:102-121. doi: 10.1016/j.addr.2018.01.011. Epub 2018 Feb 2. PMID: 29355669.

Logo -

Linda Pavy,

Source : Menarini Silicon Biosystem